Neurocrine Biosciences, Inc.
NBIX
#1404
Rank
$15.917 B
Marketcap
United States
Country
$156.59
Share price
-3.30%
Change (1 day)
2.64%
Change (1 year)
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat…
Key Metrics
Trailing P/E
21.82
Forward P/E
12.49
EPS (TTM)
$6.85
Forward EPS
$11.97
Price / Book
4.11
EV / EBITDA
16.7x
Beta
0.38
Dividend Yield
—
Return on Equity
22.09%
Return on Assets
11.70%
Debt / Equity
12.50
Current Ratio
1.87
Gross Margin
64.48%
Operating Margin
22.19%
Net Profit Margin
20.91%
Free Cash Flow
$638.238M
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 18 – Sep 16
-3.07%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$2.861B
Latest Net Income$478.600M
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Neurocrine Biosciences, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
NBIX
No recent news available. Set FINNHUB_API_KEY to enable news.
